Central Retinal Sensitivity After Intravitreal Injection of Bevacizumab for Myopic Choroidal Neovascularization

American Journal of Ophthalmology

Volumn 147, Issue 5, 2009, Pages

  Yodoi, Yuko ^a   Tsujikawa, Akitaka ^a   Nakanishi, Hideo ^a   Otani, Atsushi ^a   Tamura, Hiroshi ^a   Ojima, Yumiko ^a   Hayashi, Hisako ^a   Yoshimura, Nagahisa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MALE; MYOPIA; OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 64449084895     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.11.020     Document Type: Article

References (26)

1. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 53 (2008) 121-138
2. Chan W.M., Ohji M., Lai T.Y., et al. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 89 (2005) 1522-1528
3. Yoshida T., Ohno-Matsui K., Yasuzumi K., et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110 (2003) 1297-1305
4. Blinder K.J., Blumenkranz M.S., Bressler N.M., et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP Report No. 3. Ophthalmology 110 (2003) 667-673
5. Bevacizumab. Anti-VEGF monoclonal antibody, Avastin, rhumab-VEGF. Drugs R D 3 (2002) 28-30
6. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
7. Davidorf F.H., Mouser J.G., and Derick R.J. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26 (2006) 354-356
8. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695-1705
9. Chan W.M., Lai T.Y., Liu D.T., and Lam D.S. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114 (2007) 2190-2196
10. Hernandez-Rojas M.L., Quiroz-Mercado H., Dalma-Weiszhausz J., et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27 (2007) 707-712
11. Laud K., Spaide R.F., Freund K.B., et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26 (2006) 960-963
12. Mandal S., Venkatesh P., Sampangi R., and Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17 (2007) 620-626
13. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye. Forthcoming.
14. Sakaguchi H., Ikuno Y., Gomi F., et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91 (2007) 161-165
15. Tewari A., Dhalla M.S., and Apte R.S. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26 (2006) 1093-1094
16. Yamamoto I., Rogers A.H., Reichel E., et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91 (2007) 157-160
17. Varano M., Parisi V., Tedeschi M., et al. Macular function after PDT in myopic maculopathy: psychophysical and electrophysiological evaluation. Invest Ophthalmol Vis Sci 46 (2005) 1453-1462
18. Rohrschneider K., Springer C., Bültmann S., and Völcker H.E. Microperimetry-comparison between the Micro Perimeter-1 and scanning laser ophthalmoscope-fundus perimetry. Am J Ophthalmol 139 (2005) 125-134
19. Springer C., Bültmann S., Völcker H.E., and Rohrschneider K. Fundus perimetry with the Micro Perimeter-1 in normal individuals: comparison with conventional threshold perimetry. Ophthalmology 112 (2005) 848-854
20. Yodoi Y., Tsujikawa A., Kameda T., et al. Central retinal sensitivity measured with the Micro Perimeter-1 after photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 143 (2007) 984-994
21. Weingessel B, Sacu S, Vécsei-Marlovits PV, et al. Interexaminer and intraexaminer reliability of the microperimeter MP-1. Eye. Forthcoming.
22. Tong J.P., Chan W.M., Liu D.T., et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141 (2006) 456-462
23. Nguyen Q.D., Shah S., Tatlipinar S., et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89 (2005) 1368-1370
24. Hayashi K., Ohno-Matsui K., Teramukai S., et al. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 145 (2008) 518-526
25. Kojima A., Ohno-Matsui K., Futagami S., et al. Trans-Tenon's retrobulbar triamcinol1 infusion for myopic choroidal neovascularization. Acta Ophthalmol Scand 84 (2006) 749-754
26. Spandau U.H., and Jonas J.B. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol 142 (2006) 1068-1070